drugset / Trial / NCT03822065

A Relative Bioavailability Food Effect Study of LY03005

NCT03822065

Phase 1 Completed 34 enrolled Luye Pharma Group Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

The objective if this study is to assess the relative bio-availability of single oral doses of 80 mg LY03005 tablets administered to healthy subjects under fed versus fasted conditions in a 2-period, crossover trial.

Timeline

Start
2019-01-16
Primary completion
2019-02-16
Completion
2019-02-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Toludesvenlafaxine Small molecule 80 mg Oral